A population-based analysis on the use of therapeutic plasma exchange and intravenous immunoglobulin in heparin-induced thrombocytopenia

Arepally, 2017, Heparin-induced thrombocytopenia, Blood., 129, 2864, 10.1182/blood-2016-11-709873 Greinacher, 2009, Heparin-induced thrombocytopenia, J. Thromb. Haemost., 7, 9, 10.1111/j.1538-7836.2009.03385.x Cuker, 2018, American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia, Blood Advances., 2, 3360, 10.1182/bloodadvances.2018024489 Greinacher, 2015, Heparin-induced thrombocytopenia, N. Engl. J. Med., 373, 1882, 10.1056/NEJMcp1411910 Linkins, 2012, Treatment and prevention of heparin-induced thrombocytopenia, Chest., 141, e495S, 10.1378/chest.11-2303 Dhakal, 2018, Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study, The Lancet Haematology., 5, e220, 10.1016/S2352-3026(18)30046-2 Kuter, 2017, Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia, Am. J. Hematol., 92, 730, 10.1002/ajh.24759 Greinacher, 2017, Autoimmune heparin-induced thrombocytopenia, J. Thromb. Haemost., 15, 2099, 10.1111/jth.13813 Tun, 2012, A rare case of intracerebral hemorrhage complicating heparin-induced thrombocytopenia with thrombosis: a clinical dilemma ameliorated by novel use of plasmapheresis, Int. J. Hematol., 96, 513, 10.1007/s12185-012-1161-3 Iluonakhamhe, 2015, Plasmapheresis may be an option in urgent management of heparin-induced thrombocytopenia in the setting of acute intracerebral hemorrhage, Neurocrit. Care., 22, 140, 10.1007/s12028-014-0052-2 Welsby, 2010, Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia, Anesthesia & Analgesia, 110, 30, 10.1213/ANE.0b013e3181c3c1cd Moreno-Duarte, 2020, Clinical outcomes of cardiac surgery patients undergoing therapeutic plasma exchange for heparin-induced thrombocytopenia, Vox Sang. Dougherty, 2020, Intravenous immune globulin (IVIG) for treatment of autoimmune heparin-induced thrombocytopenia: a systematic review, Ann. Pharmacother., 106002802094354 Aryal, 2020 Onuoha, 2020, Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin-induced thrombocytopenia: a systematic review, Transfusion., 60, 2714, 10.1111/trf.16018 Warkentin, 2015, Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities, Blood., 125, 195, 10.1182/blood-2014-07-590844 Warkentin, 2018, Intravenous immune globulin to prevent heparin-induced thrombocytopenia, N. Engl. J. Med., 378, 1845, 10.1056/NEJMc1801799 Jones, 2018, Normal plasma IgG inhibits HIT antibody–mediated platelet activation: implications for therapeutic plasma exchange, Blood., 131, 703, 10.1182/blood-2017-08-803031 Rollin, 2015, Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2, Blood., 125, 2397, 10.1182/blood-2014-09-594515 Irani, 2019, Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia: IVIG THERAPY FOR SPONTANEOUS HIT, Transfusion., 59, 931, 10.1111/trf.15105 Overview of the National (Nationwide) Inpatient Sample (NIS) Elixhauser, 1998, Comorbidity measures for use with administrative data, Medical Care, 36, 8, 10.1097/00005650-199801000-00004 Dhakal, 2020, Use of IV immunoglobulin G in heparin-induced thrombocytopenia patients is not associated with increased rates of thrombosis, Chest., 158, 1172, 10.1016/j.chest.2020.03.024 Hartmann, 2020, Google trends as an early indicator for shortages of intravenous immunoglobulin (IVIG), Transfusion., 60, 1656, 10.1111/trf.15835 Edington, 2020, Dealing with a critical national shortage—approaches to triaging immune globulin supply in pediatric hematology and oncology, Pediatr Blood Cancer, 67, 10.1002/pbc.28260 Lankford, 2000, Indications for therapeutic plasma exchange at a university hospital and a regional blood center, J. Clin. Apher., 15, 242, 10.1002/1098-1101(2000)15:4<242::AID-JCA5>3.0.CO;2-Z Kundrapu, 2019, Adverse events during apheresis: a 10-year experience at a tertiary academic medical center, J. Clin. Apher., 34, 528, 10.1002/jca.21706